IL6 and scleritis: Although various reports have described the use of molecularly targeted therapies using biologics such as TNF inhibitors, IL-6 inhibitors, CTLA4Ig, anti-CD20 antibody, and anti-CD25 antibody, the optimal molecules to target with molecularly targeted therapy in scleritis have remained unknown [36,37,38,39,40].